Addressing Alzheimer's disease tangles: From NAP to AL-108

Current Alzheimer Research

Volumn 6, Issue 5, 2009, Pages 455-460

  Gozes, Illana ^a,b   Stewart, Alistair ^b   Morimoto, Bruce ^b   Fox, Anthony ^b   Sutherland, Karole ^b   Schmechel, Donald ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Allon Therapeutics Inc   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AL 108; AMYLOID PRECURSOR PROTEIN; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PEPTIDE DERIVATIVE; PLACEBO; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PRESENILIN 1; PROTEIN KINASE B; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG WITHDRAWAL; GENE EXPRESSION; HEADACHE; HUMAN; MICROTUBULE; MILD COGNITIVE IMPAIRMENT; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; NOSE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RHINOPHARYNGITIS; SIGNAL TRANSDUCTION; TAUOPATHY;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HOMEODOMAIN PROTEINS; HUMANS; MEMORY; MICE; MICROTUBULES; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; OLIGOPEPTIDES; TAU PROTEINS;

EID: 68949169111     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509789207895     Document Type: Conference Paper

References (72)

1. Gozes I. VIP, From gene to behavior and back: summarizing my 25 years of research. J Mol Neurosci 36: 115-124 (2008).
2. Gozes I, Fridkin M, Hill JM, Brenneman DE. Pharmaceutical VIP: prospects and problems. Curr Med Chem 6: 1019-1034 (1999).
3. Gozes I, Furman S. VIP and drug design. Curr Pharm Des 9: 483-494 (2003).
4. Gozes I. The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley. Expert Opin Ther Targets 11: 733-736 (2007). (Pubitemid 46901393)
5. Brenneman DE, Glazner G, Hill JM, Hauser J, Davidson A, Gozes I. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann N Y Acad Sci 865: 207-212 (1998). (Pubitemid 29047829)
6. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72: 1283-1293 (1999). (Pubitemid 29085045)
7. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276: 708-714 (2001). (Pubitemid 32050368)
8. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 97: 2299-2307 (1996).
9. Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 7: 235-244 (1996).
10. Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I. NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther 319: 332-339 (2006). (Pubitemid 44455140)
11. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293: 1091-1098 (2000). (Pubitemid 30417880)
12. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and nap promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 25: 225-238 (2005). (Pubitemid 41389347)
13. Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection. J Mol Neurosci 14: 61-68 (2000).
14. Gozes I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci 24: 700-705 (2001). (Pubitemid 33097536)
15. Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol 252: 148-153 (2006). (Pubitemid 43914096)
16. Gozes I. Activity-dependent neuroprotective protein: From gene to drug candidate. Pharmacol Ther 114: 146-154 (2007). (Pubitemid 46578333)
17. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol 1: 193-199 (2004). (Pubitemid 39424147)
18. Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci 35: 127-141 (2008).
19. Gennet N, Herden C, Bubb VJ, Quinn JP, Kipar A. Expression of activity-dependent neuroprotective protein in the brain of adult rats. Histol Histopathol 23: 309-317 (2008).
20. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2: 149-153 (2005). (Pubitemid 40862875)
21. Thippeswamy T, Howard MR, Cosgrave AS, Arora DK, McKay JS, Quinn JP. Nitric oxide-NGF mediated PPTA/SP, ADNP, and VIP expression in the peripheral nervous system. J Mol Neurosci 33: 268-277 (2007). (Pubitemid 350242536)
22. Cosgrave AS, McKay JS, Bubb V, Morris R, Quinn JP, Thippeswamy T. Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure. Neurobiol Dis 30: 281-292 (2008).
23. Dangoor D, Giladi E, Fridkin M, Gozes I. Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides 26: 2579-2584 (2005). (Pubitemid 41676734)
24. Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, et al. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 373: 73-78 (2005). (Pubitemid 39536224)
25. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 282: 34448-34456 (2007). (Pubitemid 350159432)
26. Kushnir M, Dresner E, Mandel S, Gozes I. Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem 105: 537-545 (2007).
27. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 35: 127-141 (2007).
28. Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 303: 814-824 (2007). (Pubitemid 46341287)
29. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144: 83-90 (2003). (Pubitemid 36897699)
30. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 323: 438-449 (2007). (Pubitemid 350005131)
31. Turetsky BI, Moberg PJ, Roalf DR, Arnold SE, Gur RE. Decrements in volume of anterior ventromedial temporal lobe and olfactory dysfunction in schizophrenia. Arch Gen Psychiatry 60: 1193-1200 (2003).
32. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 3: 515-533 (2004). (Pubitemid 40081279)
33. Ishizuka K, Paek M, Kamiya A, Sawa A. A review of Disrupted-In- Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol Psychiatry 59: 1189-1197 (2006). (Pubitemid 43912556)
34. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-1288 (2005). (Pubitemid 40299973)
35. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, et al. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry 60: 1224-1230 (2006). (Pubitemid 44693534)
36. Baas PW, Qiang L. Axonal transport and neurodegenerative disease. Trends Cell Biol 15: 183-187 (2006).
37. Gotz J, Ittner LM, Kins S. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem 98: 993-1006 (2006).
38. Kins S, Beyreuther K. Teasing out the tangles. Nat Med 12: 764-5; discussion 5 (2006).
39. Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279: 28531-28538 (2004). (Pubitemid 38900136)
40. Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis 6: S37-41 (2004). (Pubitemid 40202540)
41. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98: 973-984 (2006). (Pubitemid 44051296)
42. Gozes I, Spivak-Pohis I. Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate. Curr Alzheimer Res 3: 197-199 (2006). (Pubitemid 43995194)
43. Lagreze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, et al. The Peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 46: 933-938 (2005). (Pubitemid 41321030)
44. Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, et al. PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci 25: 7420-7428 (2005).
45. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 20: 315-322 (2003). (Pubitemid 38146988)
46. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003). (Pubitemid 36937044)
47. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, La-Ferla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281: 39413-39423 (2006). (Pubitemid 46041901)
48. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332 (2004). (Pubitemid 39061125)
49. Matsuoka Y, Gray A, Hirata-Fukae C, Sakura Minami S, Graeme Waterhouse E, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31: 165-170 (2007). (Pubitemid 46742300)
50. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325: 146-153 (2008).
51. Ju BG, Solum D, Song EJ, Lee KJ, Rose DW, Glass CK, et al. Activating the PARP-1 sensor component of the groucho/ TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway. Cell 119: 815-829 (2004). (Pubitemid 40017688)
52. Homburg S, Visochek L, Moran N, Dantzer F, Priel E, Asculai E, et al. A fast signal-induced activation of Poly(ADP-ribose) polymerase: a novel downstream target of phospholipase c. J Cell Biol 150: 293-307 (2000). (Pubitemid 30491354)
53. Cohen-Armon M, Visochek L, Katzoff A, Levitan D, Susswein AJ, Klein R, et al. Long-term memory requires polyADP-ribosylation. Science 304: 1820-2 (2004).
54. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 26: 882-893 (2004).
55. Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem 122: 171-193 (1993). (Pubitemid 23222327)
56. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 20: 405-411 (1995).
57. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADPribosyl) ation reactions in the regulation of nuclear functions. Biochem J 342 ( Pt 2): 249-268 (1999). (Pubitemid 29425344)
58. Satoh T, Sakai N, Enokido Y, Uchiyama Y, Hatanaka H. Free radical-independent protection by nerve growth factor and Bcl-2 of PC12 cells from hydrogen peroxide-triggered apoptosis. J Biochem (Tokyo) 120: 540-546 (1996). (Pubitemid 26331643)
59. Rouleau M, Aubin RA, Poirier GG. Poly(ADP-ribosyl)ated chromatin domains: access granted. J Cell Sci 117: 815-825 (2004). (Pubitemid 38386940)
60. Pascual M, Guerri C. The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J Neurochem 103: 557-568 (2007). (Pubitemid 47498015)
61. Ashur-Fabian O, Giladi E, Furman S, Steingart RA, Wollman Y, Fridkin M, et al. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neurosci Lett 307: 167-170 (2001). (Pubitemid 32595655)
62. Kim YM, Chung HT, Kim SS, Han JA, Yoo YM, Kim KM, et al. Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. J Neurosci 19: 6740-6747 (1999).
63. Gozes I, Steingart RA, Spier AD. NAP mechanisms of neuroprotection. J Mol Neurosci 24: 67-72 (2004).
64. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33: 1085-1092 (2002). (Pubitemid 34293596)
65. Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci 18: 37-45 (2002). (Pubitemid 34252622)
66. Zaltzman R, Beni SM, Giladi E, Pinhasov A, Steingart RA, Romano J, et al. Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport 14: 481-484 (2003). (Pubitemid 36337955)
67. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 296: 57-63 (2001). (Pubitemid 32015060)
68. Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, et al. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci 1070: 500-506 (2006). (Pubitemid 44126693)
69. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, et al. Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 309: 1190-1197 (2004). (Pubitemid 38669709)
70. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11: 353-368 (2005).
71. Morimoto BH, de Lannoy I, Liu X, Gien B, Yang Y, Fox A, et al. Pharmacokinetics of the neuroprotective peptide, NAPVSIPQ in serial samples of plasma and CSF after intravenous or intranasal administration. Drug Metab Rev 38: 213-214 (2006).
72. Schmechel DE, Burkhart DS, Ange R, Izard MK. Cholinergic axonal dystrophy and mitochondrial pathology in prosimian primates. Exp Neurol 142: 111-127 (1996). (Pubitemid 26381385)